



## **The Medicines Patent Pool Foundation**

### **Board Resolution**

23 July 2022 (via correspondence)

The Governance Board of the Medicines Patent Pool (MPP) thanks the Expert Advisory Group (EAG) for their report assessing the final results of negotiations between MPP and ViiV Healthcare Company (ViiV) on the proposed licence agreement for cabotegravir (Agreement).

The Board has reviewed the EAG report assessing the proposed Agreement. The Board agrees with the EAG's assessment that the proposed collaboration is consistent with the MPP's mandate as defined in its Statutes, and that the Agreement represents a significant improvement over the status quo. Therefore, the Board requests the Executive Director to finalise and sign the necessary documents with ViiV to formalise this collaboration, while additionally recommending that MPP continue to seek the expansion of the Territory, including with respect to the private market of the royalty-bearing countries, and urging ViiV to work with MPP on such an expansion.